T follicular helper (Tfh) cells are overactivated in systemic lupus erythematosus (SLE) patients and contribute to excessive immunity. Hematopoietic progenitor kinase 1 (HPK1), as an inhibitor of T cells, is underexpressed in SLE Tfh cells and consequently induces autoimmunity. However, the reason for downregulation of HPK1 in SLE Tfh cells remains elusive. By combining chromatin immunoprecipitation with quantitative polymerase chain reaction assays, it was found that histone H3 lysine 27 trimethylation (H3K27me3) at the HPK1 promoter in SLE Tfh cells elevated greatly. We also confirmed jumonji domain-containing 3 (JMJD3) binding at the HPK1 promoter in SLE Tfh cells reduced profoundly. Knocking down JMJD3 in normal Tfh cells with siRNA alleviated enrichments of JMJD3, H3K4me3, and mixed-lineage leukemia (MLL) 1 at the HPK1 promoter and increased H3K27me3 number in the region. HPK1 expression was lowered, while Tfh cell proliferation activity, IL-21 and IFNγ secretions in the supernatants of Tfh cells, and IgG1 and IgG3 concentrations in the supernatants of Tfh-B cell cocultures all upregulated markedly. In contrast, elevating JMJD3 amount in SLE Tfh cells by JMJD3-overexpressed plasmid showed opposite effects. The abundances of H3K4me3 and MLL1 at the HPK1 promoter in SLE Tfh cells were greatly attenuated. Our results suggest that deficient JMJD3 binding at the promoter dampens HPK1 expression in SLE Tfh cells, thus making Tfh cells overactive, and ultimately results in onset of SLE.
Henoch‐Schönlein purpura (HSP) is an inflammatory condition affecting the small blood vessels, leading to organ damage and symptoms across various body systems, including skin, joints, and kidneys. The disease’s pathogenesis involves the deposition of immunoglobulin (Ig) A immune complexes in vessels, triggering inflammation and damage. Recent research highlights the role of T follicular helper cells (Tfh cells) in HSP. The review delves into Tfh cells’ biological functions, emphasizing their involvement in the HSP’s development by activating autoreactive B cells and inducing the production of autoantibodies through the secretion of interleukin (IL)‐21, IL‐4, and IL‐6. Additionally, the roles of different Tfh cell subsets in the pathogenesis of HSP are also characterized by their unique features. We also highlight the relationship between Tfh cells and galactose‐deficient IgA1 (Gd‐IgA1) production, compare Tfh‐mediated immune responses in HSP with those in IgA nephropathy (IgAN) and systemic lupus erythematosus (SLE), and discuss emerging therapeutic strategies targeting the Tfh–B‐cell axis. It concludes by suggesting the need for further research on Tfh cells to understand HSP pathogenesis better and develop effective treatments.